AstraZeneca (AZ) is a global, research-driven biopharmaceutical company committed to advancing science and improving patient outcomes. This 60-minute breakout session will provide an evidence-based update on recent developments across AZ’s Biopharmaceuticals and Oncology portfolios, emphasizing clinical value, unmet need, and implications for evidence-based formulary, utilization, and access decisions in federal and related integrated care delivery systems. Part 1: Biopharmaceuticals Unit (Cardiorenal Metabolism and Respiratory) We will review late-stage and emerging therapies targeting key drivers of cardiovascular and respiratory disease burden. In hypertension, we will discuss an oral, mechanism-based approach designed to address persistent blood pressure elevation in patients on multidrug regimens, with a focus on efficacy, safety, and potential impact on control rates, monitoring, and care pathways in integrated systems. In dyslipidemia, we will examine an oral nonstatin strategy that has shown clinically meaningful LDL C reductions as monotherapy and as an adjunct to statins, with attention to positioning in stepwise lipid lowering algorithms, adherence considerations, and potential implications for population-health management. In COPD, we will highlight a biologically targeted therapy that modulates upstream epithelial and inflammatory signaling associated with exacerbations, exploring the potential to reduce acute care utilization, improve quality of life, and inform pathway alignment and access decisions. Part 2: Oncology Business Unit AZ is advancing a comprehensive oncology strategy focused on delivering transformative therapies across multiple tumor types through scientific innovation and strategic collaboration. This part will highlight the company’s clinical development approach with emphasis on thoracic malignancies and near term studies, including an antibody drug conjugate platform in lung cancer designed to address critical unmet needs through targeted delivery. Attendees will gain insight into the late stage pipeline, recent data releases, and opportunities for collaboration with federal accounts to enhance access to cutting edge therapies for veterans. The discussion will underscore the value of sustained collaboration between AZ and federal accounts in driving innovation, accelerating research, and improving outcomes in oncology, including operational considerations for pathway alignment, diagnostics integration, and care coordination. Across both parts, presenters will integrate clinical evidence to support transparent, data driven decisions. Time will be reserved and the end of the presentation to answer questions in both therapeutic areas.